TY-2136b

A Phase I, Multicenter, Open-label Study of TY-2136b, Administered Orally in Patients With Advanced or Metastatic Solid Tumors Harboring ALK, ROS1 or NTRK1-3 Alterations

What's the purpose of the trial?

The primary objective of this study is to evaluate the safety and tolerability of TY-2136b and to determine the recommended phase 2 dose (RP2D), with dose-escalation stage and dose-expansion stage.

Trial status

Accepting patients

Phase

Phase 1

Enrollment

282

Last Updated

3 months ago

Am I Eligible

Participating Centers

There are 2 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

TY-2136b is a drug currently in development that targets ROS1/NTRK/ALK gene changes.

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

NTRK 1-3 Gene

Accepting patients

EXPERIMENTAL: Escalation stage

Accepting patients

EXPERIMENTAL: Expansion stage

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print this trial to share with your doctor.

(831) 888-0898

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.